Krishnansu S. Tewari, MD, a professor of obstetrics and gynecology at the University of California Irvine in Orange, California, discusses the effectiveness of bevacizumab in relapsed and metastatic cervical cancer.

A phase III trial performed by the GOG compared chemotherapy alone to chemotherapy plus bevacizumab. Overall, the median overall survival for patients who received bevacizumab plus chemotherapy was 17.0 months compared 13.3 months. Indicating an effective biologic agent where none previously existed, Tewari explains.

View more from the 2013 ASCO Annual Meeting

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gynecologic Oncology

CLO-22-OSD1210 - /clinical/gynecologic-oncology

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

ASCO Annual Meeting

Krishnansu S. Tewari, MD, from the University of California Irvine in Orange, California, discusses the effectiveness of bevacizumab in relapsed and metastatic cervical cancer.

Dr. Tewari on Bevacizumab in Advanced Cervical Cancer